Asuka Oda

1.0k total citations
36 papers, 693 citations indexed

About

Asuka Oda is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Asuka Oda has authored 36 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 24 papers in Hematology and 14 papers in Oncology. Recurrent topics in Asuka Oda's work include Multiple Myeloma Research and Treatments (24 papers), Bone health and treatments (7 papers) and Cancer Mechanisms and Therapy (5 papers). Asuka Oda is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Bone health and treatments (7 papers) and Cancer Mechanisms and Therapy (5 papers). Asuka Oda collaborates with scholars based in Japan, United States and Mongolia. Asuka Oda's co-authors include Masahiro Abe, Toshio Matsumoto, Shuji Ozaki, Kyoko Takeuchi, Ayako Nakano, Hiroe Amou, Masahiro Hiasa, Kumiko Kagawa, Takeshi Harada and Hirokazu Miki and has published in prestigious journals such as Blood, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Asuka Oda

36 papers receiving 679 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Asuka Oda Japan 13 353 310 281 142 120 36 693
Hiroe Amou Japan 11 319 0.9× 301 1.0× 251 0.9× 126 0.9× 96 0.8× 16 633
Jumpei Teramachi Japan 17 368 1.0× 228 0.7× 112 0.4× 90 0.6× 64 0.5× 45 622
Shaoyan Hu China 17 428 1.2× 103 0.3× 209 0.7× 218 1.5× 150 1.3× 76 715
Chiqi Chen China 17 479 1.4× 142 0.5× 193 0.7× 244 1.7× 180 1.5× 34 792
Maria Teresa Esposito United Kingdom 9 473 1.3× 159 0.5× 145 0.5× 56 0.4× 60 0.5× 19 617
Na Luo China 13 373 1.1× 115 0.4× 262 0.9× 180 1.3× 126 1.1× 22 715
Ida Katrine Lund Denmark 18 335 0.9× 264 0.9× 97 0.3× 356 2.5× 132 1.1× 43 839
Patrycja Pawlikowska France 15 391 1.1× 177 0.6× 134 0.5× 137 1.0× 61 0.5× 24 682
Claudia Gemelli Italy 18 289 0.8× 114 0.4× 68 0.2× 77 0.5× 143 1.2× 24 561
Juraj Adamik United States 17 278 0.8× 189 0.6× 86 0.3× 70 0.5× 212 1.8× 36 562

Countries citing papers authored by Asuka Oda

Since Specialization
Citations

This map shows the geographic impact of Asuka Oda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asuka Oda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asuka Oda more than expected).

Fields of papers citing papers by Asuka Oda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Asuka Oda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asuka Oda. The network helps show where Asuka Oda may publish in the future.

Co-authorship network of co-authors of Asuka Oda

This figure shows the co-authorship network connecting the top 25 collaborators of Asuka Oda. A scholar is included among the top collaborators of Asuka Oda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Asuka Oda. Asuka Oda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Teramachi, Jumpei, Masahiro Hiasa, Asuka Oda, et al.. (2025). Myeloma cell growth suppression by osteoblast-derived extracellular vesicles: the creation of a non-permissive niche for myeloma cells by bone-forming osteoblasts. Haematologica. 110(6). 1395–1401. 1 indexed citations
2.
Inoue, Yusuke, Jumpei Teramachi, Asuka Oda, et al.. (2024). Elotuzumab‐mediated ADCC with Th1‐like Vγ9Vδ2 T cells to disrupt myeloma–osteoclast interaction. Cancer Science. 116(2). 559–563. 1 indexed citations
3.
Inoue, Yusuke, Asuka Oda, Kimiko Sogabe, et al.. (2024). Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid. International Journal of Hematology. 119(6). 626–630. 1 indexed citations
4.
Harada, Takeshi, Yusuke Inoue, Asuka Oda, et al.. (2024). Steric Hindrance By APRIL in Binding of BCMA-Directed Bispecific Antibodies: A Novel Refractory Mechanism of BCMA-Directed Immunotherapies in Multiple Myeloma. Blood. 144(Supplement 1). 1884–1884. 1 indexed citations
5.
Teramachi, Jumpei, Masahiro Hiasa, Takeshi Harada, et al.. (2023). Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors. International Journal of Hematology. 118(1). 88–98. 3 indexed citations
6.
Tanimoto, Kotaro, Masahiro Hiasa, Jumpei Teramachi, et al.. (2021). Mechanical unloading aggravates bone destruction and tumor expansion in myeloma. Haematologica. 107(3). 744–749. 3 indexed citations
7.
Teramachi, Jumpei, Masahiro Hiasa, Asuka Oda, et al.. (2020). TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma. Haematologica. 106(5). 1401–1413. 25 indexed citations
8.
Ishikawa, Masaya, et al.. (2015). Factors contributing to deep supercooling capability and cold survival in dwarf bamboo (Sasa senanensis) leaf blades. Frontiers in Plant Science. 5. 791–791. 5 indexed citations
9.
Harada, Takeshi, Shuji Ozaki, Asuka Oda, et al.. (2013). Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors. PLoS ONE. 8(12). e83905–e83905. 13 indexed citations
10.
Harada, Takeshi, Shuji Ozaki, Asuka Oda, et al.. (2013). Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. International Journal of Hematology. 97(6). 743–748. 20 indexed citations
11.
Nakano, Ayako, Hirokazu Miki, Shingen Nakamura, et al.. (2012). Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. Journal of Bioenergetics and Biomembranes. 44(1). 31–38. 36 indexed citations
12.
Kagawa, Kumiko, Ayako Nakano, Hirokazu Miki, et al.. (2012). Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL. PLoS ONE. 7(2). e31594–e31594. 10 indexed citations
13.
Miki, Hirokazu, Shuji Ozaki, Shingen Nakamura, et al.. (2011). KRN5500, a spicamycin derivative, exerts anti‐myeloma effects through impairing both myeloma cells and osteoclasts. British Journal of Haematology. 155(3). 328–339. 4 indexed citations
14.
Nakano, Ayako, Masahiro Abe, Asuka Oda, et al.. (2011). Delayed treatment with vitamin C and N-acetyl-l-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib. International Journal of Hematology. 93(6). 727–735. 22 indexed citations
15.
Cui, Qu, Hironobu Shibata, Asuka Oda, et al.. (2011). Targeting myeloma–osteoclast interaction with Vγ9Vδ2 T cells. International Journal of Hematology. 94(1). 63–70. 12 indexed citations
16.
Nakano, Ayako, Daisuke Tsuji, Hirokazu Miki, et al.. (2011). Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells. PLoS ONE. 6(11). e27222–e27222. 90 indexed citations
17.
Takeuchi, Kyoko, Masahiro Abe, Masahiro Hiasa, et al.. (2010). TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth. PLoS ONE. 5(3). e9870–e9870. 108 indexed citations
18.
Kitazoe, Ken-ichi, Masahiro Abe, Masahiro Hiasa, et al.. (2008). Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. International Journal of Hematology. 89(1). 45–57. 25 indexed citations
19.
Tanaka, Yoïchi, Masahiro Abe, Masahiro Hiasa, et al.. (2007). Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin. Clinical Cancer Research. 13(3). 816–823. 129 indexed citations
20.
Takeuchi, Kyoko, Masahiro Abe, Asuka Oda, et al.. (2006). SB431542, a TGF-Beta Receptor Kinase Inhibitor, Restores Bone Formation Which Ameliorates Myeloma-Induced Microenvironment.. Blood. 108(11). 3479–3479. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroe Amou Breakdown of academic impact, for papers by Jumpei Teramachi Breakdown of academic impact, for papers by Shaoyan Hu Breakdown of academic impact, for papers by Chiqi Chen Breakdown of academic impact, for papers by Maria Teresa Esposito Breakdown of academic impact, for papers by Na Luo Breakdown of academic impact, for papers by Ida Katrine Lund Breakdown of academic impact, for papers by Patrycja Pawlikowska Breakdown of academic impact, for papers by Claudia Gemelli Breakdown of academic impact, for papers by Juraj Adamik
Rankless by CCL
2026